- CERO Therapeutics Holdings, Inc. published an updated investor presentation on **September 22, 2025**, detailing its **Chimeric Engulfment Receptor T cells (CER-T) platform**.  **[1870404_0001213900-25-090107_ea0258166-8k_cero.htm:1]** **[1870404_0001213900-25-090107_ea025816601ex99-1_cero.htm:5]** 
- The company anticipates several clinical catalysts, including the enrollment of the **second and third patients in a Phase 1 Acute Myeloid Leukemia (AML) trial in 3Q 2025**, the **fourth patient in 4Q 2025**, and the **initiation of a Phase 1 trial in Ovarian and Non-Small Cell Lung Cancer in Q1 2026**.  **[1870404_0001213900-25-090107_ea025816601ex99-1_cero.htm:5]** 
- Initial patient data for Ovarian and Non-Small Cell Lung Cancer is **expected in 2H 2026**.  **[1870404_0001213900-25-090107_ea025816601ex99-1_cero.htm:5]** 
- The CER-T platform has demonstrated **robust preclinical tumor-killing capabilities** across liquid and solid tumors, with encouraging Phase 1 data in AML showing an immune response.  **[1870404_0001213900-25-090107_ea025816601ex99-1_cero.htm:5]**

CERO THERAPEUTICS HOLDINGS (CERO)